SAR 441121
Alternative Names: MMV 533; MMV688533; SAR121; SAR441121Latest Information Update: 02 Jan 2024
At a glance
- Originator Sanofi
- Class Antimalarials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Malaria
Most Recent Events
- 22 Dec 2023 SAR 441121 is still in phase-I trials for Malaria (In volunteers) in Australia (MMV pipeline, December 2023)
- 22 Dec 2023 Medicines for Malaria Venture plans a phase-II trial for Malaria (MMV pipeline, December 2023)
- 25 Jan 2022 Medicines for Malaria Venture plans a phase I trial for Malaria (In volunteers) in Australia (PO) in February 2022 (NCT05205941)